Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), Xoma (XOMA) and Novavax (NVAX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report), Xoma (XOMA – Research Report) and Novavax (NVAX – Research Report).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Alkermes (ALKS)
In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Alkermes, with a price target of $40.00. The company’s shares closed last Wednesday at $30.98.
According to TipRanks.com, Thome is a 5-star analyst with an average return of
Alkermes has an analyst consensus of Moderate Buy, with a price target consensus of $43.33, a 54.9% upside from current levels. In a report issued on October 28, RBC Capital also maintained a Buy rating on the stock with a $47.00 price target.
See today’s best-performing stocks on TipRanks >>
Xoma (XOMA)
TD Cowen analyst Phil Nadeau maintained a Hold rating on Xoma today. The company’s shares closed last Wednesday at $32.96, close to its 52-week high of $35.00.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xoma with a $69.67 average price target.
Novavax (NVAX)
In a report issued on November 7, Geoff Meacham from Citi maintained a Sell rating on Novavax, with a price target of $6.00. The company’s shares closed last Wednesday at $7.24.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Currently, the analyst consensus on Novavax is a Moderate Buy with an average price target of $12.00, implying a 62.4% upside from current levels. In a report issued on November 6, Bank of America Securities also reiterated a Sell rating on the stock with a $7.00 price target.
Read More on ALKS:
